Seasonal allergic rhinitis and its control with antihistamines in an outpatient practice.
- Authors: Nenasheva N.M.1, Shartanova N.V.2, Ovchinnikov A.Y.3, Osipova G.L.4, Zhestkov A.V.5, Pavlova N.V.6
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- NRC Institute of Immunology FMBA of Russia
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Pulmonology Scientific Research Institute under FMBA of Russia
- Samara State Medical University of the Ministry of Health of the Russian Federation
- Dr. Reddy’s Laboratories LLC
- Issue: Vol 17, No 2 (2020)
- Pages: 44-52
- Section: Original studies
- URL: https://rusalljournal.ru/raj/article/view/1370
- DOI: https://doi.org/10.36691/RJA1370
- Cite item
Allergic rhinitis (AR) is a significant social and medical problem of modern healthcare. The treatment of patients with AR is based on a stepwise approach, the purpose of which is to fully control the symptoms. The first stage drugs of choice are oral non-sedative antihistamines of the second generation. A study was conducted to evaluate the effectiveness of Allerway and drugs containing cetirizine to control the symptoms of seasonal AR (SAR) in an outpatient practice. The data obtained in the framework of a multicenter prospective noninterventional study (the short name of the study is LEVADA) were analyzed. Data were collected at 5 centers using scales for assessement of the symptoms of allergic rhinitis: rTNSS, miniRQLQ, visual analog scale and the Epworth sleepiness scale. The dynamics of SAR symptoms was assessed using the rTNSS scale (24 hours) after 7 and 14 days of treatment. A total of 100 patients were included in the study; 97 patients completed the study. Of these, 46 (47.42%) were women and 51 (52.57%) were men aged ≥18 years. The average duration of the diagnosis of SAR in patients before inclusion in the study in the Allerway group was 97.4±85.51 months (about 8 years), in the cetirizine group 107.0±114.62 months (about 8.9 years), p=0.641. The efficacy of regressing the intensity of SAR symptoms on the rTNSS scale was demonstrated to be (average and average error) –2.92±0.11 points in the group of patients taking Allerway and –2.93±0.11 points in the group of patients taking cetirizine. After 7 days, there was an increase in the proportion of patients with a complete absence of the main symptoms of SAR: nasal congestion, rhinorrhea, itching in the nose. In the group of patients taking Allerway in 44 out of 49 patients (89.8%), it was noted that on average, after 39.4±14.35 minutes, symptom relief was observed in 42 of 48 (87.5%) patients, and in patients taking cetirizine, relief of rhinitis symptoms was noted during 44.0±13.76 minutes. An improvement in the quality of life was noted by reducing the severity of symptoms on the miniRQLQ scale by 44.3±15.29 points in the Allerway group and by –45.0±13.03 in the group receiving cetirizine. It was shown that the use of Allerway (at a dose of 5 mg, once a day) and preparations containing cetirizine (at a dose of 10 mg, with a single dose per day), allows to achieve a positive clinical effect in the treatment of patients with SAR (seasonal allergic rhinitis) in outpatient practice within 7 and 14 days with a high level of safety and compliance.
Natalia M. NenashevaRussian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Department of Allergology and Immunology, Head of Department, Professor, Doctor of Medical Sciences
Natalia V. ShartanovaNRC Institute of Immunology FMBA of Russia
Head of the outpatient department, Doctor of Medical Sciences
Andrey Yu. OvchinnikovA.I. Yevdokimov Moscow State University of Medicine and Dentistry
Faculty of Medicine, Department of Otorhinolaryngology, Head of Department, Professor, Doctor of Medical Sciences
Galina L. OsipovaPulmonology Scientific Research Institute under FMBA of Russia
Head of the Clinical Research Department, Doctor of Medical Sciences
Alexander V. ZhestkovSamara State Medical University of the Ministry of Health of the Russian Federation
MD, PhD, Professor, head of Department of General and Clinical Microbiology, Immunology and Allergology
Nadezhda V. PavlovaDr. Reddy’s Laboratories LLC
- Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466-476. doi: 10.1016/j.jaci.2010.06.047.
- Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis. Allergologia et Immunopathologia. 2013;41(2):73-85. doi: 10.1016/j.aller.2012.03.001.
- Bousquet J, Khaltaev N, Cruz A et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63:8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
- Allergologiya. Federal′nyye klinicheskiye rekomendatsii. Khaitov R.M., Ilina N.I. Farmarus Print Media. 2014:126 (in Russ.).
- Ilina NI, Kurbacheva OM, Pavlova KS, Polner SA. Federal Clinical Recommendations. Allergic rhinitis. Russian Journal of Allergy. 2018;(4):43-53 (in Russ.). doi: 10.36691/rja135.
- Yanayeva KhA, Macharadze DSh, Avilov KK. Sezonnyy allergicheskiy rinit: lokalnyye osobennosti. Lechashchiy vrach. 2018;3:73-76 (in Russ.).
- The prevalence rate and etiologic spectrum of pollen allergy in the Komi Republic. Vakhnina Olga A., Fassakhov Rustem S. Vestnik sovremennoy klinicheskoy Medicine. 2014;7:3 (in Russ.). doi: 10.20969/vskm.2014.7(3).13-15.
- Goryachkina LA, Borzova EYu. Allergicheskiye reaktsii v praktike vracha. Vrach. 2003;1:5-8 (in Russ.).
- Allergic Rhinitis and its Impact on Asthma. WHO initiativе. 2001.
- US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Allergic rhinitis: developing drug products for treatment. Guidance for industry 2018. Available at: https://www.fda.gov/downloads/drugs/guidances/ucm071293.pdf. Accessed 26. 08.2019.
- Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the mini rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy. 2000;30(1):132-140. doi: 10.1046/j.1365-2222.2000.00668.x.
- Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale (PDF). Sleep. 1991;14(6):540-545. doi: 10.1093/sleep/14.6.540. PMID 1798888.
- Ganesh S, Pentewar G, Wagh R, Chincholkar AS. Pharmacoeconomic assessment and comparing efficacy between cetirizine, levocetirizine, loratadine and fexofenadine in allergic rhinitis patients International Journal of Basic & Clinical Pharmacology. 2017;6(11):2684. doi: 10.18203/2319-2003.ijbcp20174788
- Kareva EN. Vybor antigistaminnogo preparata: vzglyad farmakologa. RMZH. 2016;12:811-816 (in Russ.).
- GRLS, Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Allervey, tabletki, pokrytyye plenochnoy obolochkoy (in Russ.). http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e56ce6e7-bc3c-45b9-986a-d9a9811c2500&t=.
There are no supplementary files to display.